###
中国临床研究:2026,39(10):1493-1496,1502
本文二维码信息
码上扫一扫!
正元胶囊对晚期肺癌患者化疗后食欲减退及癌因性疲乏的影响
(1. 南京医科大学第一附属医院肿瘤科,江苏 南京 210029;2. 南京医科大学,江苏 南京 211166)
Effect of Zhengyuan capsules on post-chemotherapy appetite loss and cancer-related fatigue in patients with advanced lung cancer
摘要
本文已被:浏览 217次   下载 161次
投稿时间:2025-11-20   网络发布日期:2026-10-23
中文摘要: 目的  评估正元胶囊对晚期肺癌标准化疗后患者食欲减退及癌因性疲乏的临床疗效。方法  收集2025年3月至9月于南京医科大学第一附属医院肿瘤科接受化疗的110例晚期肺癌患者的临床资料。根据治疗方案将患者分为对照组(55 例,接受标准化疗)和试验组(55 例,在对照组基础上加用正元胶囊口服21 d)。使用食欲/进食量视觉模拟评分量表和简明疲乏量表(BFI)于化疗开始后第1 天(d1)和第7 天(d7)评估食欲减退及疲乏程度变化,同时分析慢性炎症指标纤维蛋白原/白蛋白比值(FAR)。结果  两组基线特征差异无统计学意义(P>0.05)。化疗后d1,两组患者食欲、进食量及疲乏评分差异无统计学意义(P>0.05);而化疗后d7,试验组食欲评分、进食量评分均显著高于对照组[8(8,8)分vs 2(2,2)分,Z=9.902,P<0.01;6(6,6)分vs 3(3,3)分,Z=9.706,P<0.01];疲乏评分显著低于对照组[1(1,1)分vs 4(4,4)分,Z=9.293,P<0.01]。试验组FAR显著低于对照组[0.08(0.07,0.09)vs 0.10(0.08,0.10),P=0.031]。以FAR=0.09 为阈值,将110 例患者分为高FAR 组(FAR≥0.09,n=57)和低FAR组(FAR<0.09,n=53),比较结果示d7时高FAR组BFI评分更高[4(1,4)分vs 1(1,4)分,P=0.029]。结论  正元胶囊能显著改善晚期肺癌标准化疗患者的食欲减退及癌因性疲乏,其机制可能与降低慢性炎症相关。
Abstract:Objective To evaluate the clinical efficacy of Zhengyuan capsules in improving appetite loss and cancer-related fatigue in patients with advanced lung cancer receiving standard chemotherapy. Methods Clinical data were collected from 110 advanced lung cancer patients who received chemotherapy in the Oncology Department of the First Affiliated Hospital with Nanjing Medical University from March 2025 to September 2025. Patients were divided into the control group(55 cases receiving standard chemotherapy)and the experimental group(55 cases receiving Zhengyuan capsules orally for 21 days in addition to the same standard chemotherapy of control group). Visual Analogue Scale for appetite/food intake and Brief Fatigue Inventory(BFI)were used to assess changes in appetite loss and fatigue severity on day 1(d1)and day 7(d7)of chemotherapy,while chronic inflammatory index fibrinogen-to-albumin ratio(FAR)was analyzed. Results Baseline characteristics showed no significant difference between the two groups(P>0.05). On d1 of chemotherapy,there was no statistically significant difference in appetite,food intake and fatigue score between the two groups(P>0.05). On d7 of chemotherapy,the experimental group demonstrated significantly higher appetite score[8(8,8)vs 2(2,2),Z=9.902,P<0.01]and food intake score[6(6,6)vs 3(3,3),Z=9.706,P<0.01],and significantly lower fatigue score[1(1,1)vs 4(4,4),Z=9.293,P<0.01]compared with the control group. The FAR in the experimental group was significantly lower than that in the control group[0.08(0.07,0.09)vs 0.10(0.08,0.10),P=0.031]. Using FAR=0.09 as the cutoff value,110 patients were divided into a high-FAR group(FAR≥0.09,n=57)and a low-FAR group(FAR<0.09,n=53). The high-FAR group had a higher d7 BFI score compared to the low-FAR group[4(1,4)vs 1(1,4),P=0.029]. Conclusion Zhengyuan capsules can significantly improve appetite loss and cancer-related fatigue in advanced lung cancer patients undergoing standard chemotherapy,and its mechanism may be associated with reducing chronic inflammation.
文章编号:     中图分类号:R734.2    文献标志码:A
基金项目:白求恩·双创融生-科研基金(2024-YJ-220-J-001);南京医科大学大学生创新创业训练计划项目(X2025103120156)
附件
引用文本:
焦艺,张哲源,袁露鸿樱,等.正元胶囊对晚期肺癌患者化疗后食欲减退及癌因性疲乏的影响[J].中国临床研究,2026,39(10):1493-1496,1502.

用微信扫一扫

用微信扫一扫